Unity Biotechnology

Unity Biotechnology was founded on the senolytic thesis — that selectively eliminating senescent ('zombie') cells could meaningfully extend healthspan by removing chronic pro-inflammatory pressure. Early-stage candidates targeted age-related conditions like osteoarthritis and macular degeneration; clinical results have been mixed.

The broader senolytic field has shifted toward small-molecule combinations (dasatinib + quercetin, fisetin) for systemic indications and toward FOXO4-DRI (a peptide candidate) for mechanism-of-action research, while Unity's clinical programs have narrowed to ophthalmologic indications. The company is included in this directory as the public-equity proxy for the senolytic biotech category — investors and patients tracking the senolytic literature watch UBX as the index ticker, even when the specific clinical program differs from the headline science.